Cargando…

Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years

Inflammatory Bowel Diseases had their first peak in incidence in countries in North America, Europe, and Oceania and are currently experiencing a new acceleration in incidence, especially in Latin America and Asia. Despite technological advances, 90 years after the development of the first molecule...

Descripción completa

Detalles Bibliográficos
Autores principales: Imbrizi, Marcello, Magro, Fernando, Coy, Claudio Saddy Rodrigues
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537095/
https://www.ncbi.nlm.nih.gov/pubmed/37765080
http://dx.doi.org/10.3390/ph16091272
_version_ 1785113022481563648
author Imbrizi, Marcello
Magro, Fernando
Coy, Claudio Saddy Rodrigues
author_facet Imbrizi, Marcello
Magro, Fernando
Coy, Claudio Saddy Rodrigues
author_sort Imbrizi, Marcello
collection PubMed
description Inflammatory Bowel Diseases had their first peak in incidence in countries in North America, Europe, and Oceania and are currently experiencing a new acceleration in incidence, especially in Latin America and Asia. Despite technological advances, 90 years after the development of the first molecule for the treatment of IBD, we still do not have drugs that promote disease remission in a generalized way. We carried out a narrative review on therapeutic advances in the treatment of IBD, the mechanisms of action, and the challenges facing the therapeutic goals in the treatment of IBD. Salicylates are still used in the treatment of Ulcerative Colitis. Corticosteroids have an indication restricted to the period of therapeutic induction due to frequent adverse events, while technologies with less systemic action have been developed. Most immunomodulators showed a late onset of action, requiring a differentiated initial strategy to control the disease. New therapeutic perspectives emerged with biological therapy, initially with anti-TNF, followed by anti-integrins and anti-interleukins. Despite the different mechanisms of action, there are similarities between the general rates of effectiveness. These similar results were also evidenced in JAK inhibitors and S1p modulators, the last therapeutic classes approved for the treatment of IBD.
format Online
Article
Text
id pubmed-10537095
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105370952023-09-29 Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years Imbrizi, Marcello Magro, Fernando Coy, Claudio Saddy Rodrigues Pharmaceuticals (Basel) Review Inflammatory Bowel Diseases had their first peak in incidence in countries in North America, Europe, and Oceania and are currently experiencing a new acceleration in incidence, especially in Latin America and Asia. Despite technological advances, 90 years after the development of the first molecule for the treatment of IBD, we still do not have drugs that promote disease remission in a generalized way. We carried out a narrative review on therapeutic advances in the treatment of IBD, the mechanisms of action, and the challenges facing the therapeutic goals in the treatment of IBD. Salicylates are still used in the treatment of Ulcerative Colitis. Corticosteroids have an indication restricted to the period of therapeutic induction due to frequent adverse events, while technologies with less systemic action have been developed. Most immunomodulators showed a late onset of action, requiring a differentiated initial strategy to control the disease. New therapeutic perspectives emerged with biological therapy, initially with anti-TNF, followed by anti-integrins and anti-interleukins. Despite the different mechanisms of action, there are similarities between the general rates of effectiveness. These similar results were also evidenced in JAK inhibitors and S1p modulators, the last therapeutic classes approved for the treatment of IBD. MDPI 2023-09-08 /pmc/articles/PMC10537095/ /pubmed/37765080 http://dx.doi.org/10.3390/ph16091272 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Imbrizi, Marcello
Magro, Fernando
Coy, Claudio Saddy Rodrigues
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
title Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
title_full Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
title_fullStr Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
title_full_unstemmed Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
title_short Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
title_sort pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537095/
https://www.ncbi.nlm.nih.gov/pubmed/37765080
http://dx.doi.org/10.3390/ph16091272
work_keys_str_mv AT imbrizimarcello pharmacologicaltherapyininflammatoryboweldiseasesanarrativereviewofthepast90years
AT magrofernando pharmacologicaltherapyininflammatoryboweldiseasesanarrativereviewofthepast90years
AT coyclaudiosaddyrodrigues pharmacologicaltherapyininflammatoryboweldiseasesanarrativereviewofthepast90years